Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97


CCN6 (WISP3) decreases ZEB1-mediated EMT and invasion by attenuation of IGF-1 receptor signaling in breast cancer.

Lorenzatti G, Huang W, Pal A, Cabanillas AM, Kleer CG.

J Cell Sci. 2011 May 15;124(Pt 10):1752-8. doi: 10.1242/jcs.084194. Epub 2011 Apr 26.


Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1.

Huang W, Zhang Y, Varambally S, Chinnaiyan AM, Banerjee M, Merajver SD, Kleer CG.

Am J Pathol. 2008 Apr;172(4):893-904. doi: 10.2353/ajpath.2008.070899. Epub 2008 Mar 5.


Blockade of CCN6 (WISP3) activates growth factor-independent survival and resistance to anoikis in human mammary epithelial cells.

Huang W, Gonzalez ME, Toy KA, Banerjee M, Kleer CG.

Cancer Res. 2010 Apr 15;70(8):3340-50. doi: 10.1158/0008-5472.CAN-09-4225.


CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancer.

Kleer CG, Zhang Y, Merajver SD.

Cells Tissues Organs. 2007;185(1-3):95-9. Review.


CCN6 enhances ICAM-1 expression and cell motility in human chondrosarcoma cells.

Fong YC, Lin CY, Su YC, Chen WC, Tsai FJ, Tsai CH, Huang CY, Tang CH.

J Cell Physiol. 2012 Jan;227(1):223-32. doi: 10.1002/jcp.22720.


MMTV-cre;Ccn6 knockout mice develop tumors recapitulating human metaplastic breast carcinomas.

Martin EE, Huang W, Anwar T, Arellano-Garcia C, Burman B, Guan JL, Gonzalez ME, Kleer CG.

Oncogene. 2017 Apr 20;36(16):2275-2285. doi: 10.1038/onc.2016.381. Epub 2016 Nov 7.


WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer.

Kleer CG, Zhang Y, Pan Q, Gallagher G, Wu M, Wu ZF, Merajver SD.

Breast Cancer Res. 2004;6(1):R110-5.


The matricellular protein CCN6 (WISP3) decreases Notch1 and suppresses breast cancer initiating cells.

Huang W, Martin EE, Burman B, Gonzalez ME, Kleer CG.

Oncotarget. 2016 May 3;7(18):25180-93. doi: 10.18632/oncotarget.7734.


CCN6 modulates BMP signaling via the Smad-independent TAK1/p38 pathway, acting to suppress metastasis of breast cancer.

Pal A, Huang W, Li X, Toy KA, Nikolovska-Coleska Z, Kleer CG.

Cancer Res. 2012 Sep 15;72(18):4818-28. doi: 10.1158/0008-5472.CAN-12-0154. Epub 2012 Jul 17.


Insulin-like growth factor-binding protein-3 promotes transforming growth factor-{beta}1-mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal cells.

Natsuizaka M, Ohashi S, Wong GS, Ahmadi A, Kalman RA, Budo D, Klein-Szanto AJ, Herlyn M, Diehl JA, Nakagawa H.

Carcinogenesis. 2010 Aug;31(8):1344-53. doi: 10.1093/carcin/bgq108. Epub 2010 May 31.


IGF-I differentially regulates IGF-binding protein expression in primary mammary fibroblasts and epithelial cells.

Fleming JM, Leibowitz BJ, Kerr DE, Cohick WS.

J Endocrinol. 2005 Jul;186(1):165-78.


Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail.

Kim HJ, Litzenburger BC, Cui X, Delgado DA, Grabiner BC, Lin X, Lewis MT, Gottardis MM, Wong TW, Attar RM, Carboni JM, Lee AV.

Mol Cell Biol. 2007 Apr;27(8):3165-75. Epub 2007 Feb 12.


Insulin-like growth factor-binding protein enhancement of insulin-like growth factor-I (IGF-I)-mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line.

Chen JC, Shao ZM, Sheikh MS, Hussain A, LeRoith D, Roberts CT Jr, Fontana JA.

J Cell Physiol. 1994 Jan;158(1):69-78.


PAX5alpha enhances the epithelial behavior of human mammary carcinoma cells.

Vidal LJ, Perry JK, Vouyovitch CM, Pandey V, Brunet-Dunand SE, Mertani HC, Liu DX, Lobie PE.

Mol Cancer Res. 2010 Mar;8(3):444-56. doi: 10.1158/1541-7786.MCR-09-0368. Epub 2010 Mar 2.

Supplemental Content

Support Center